Clinical benefit of NMDA receptor antagonists in a patient with ATP1A2 gene mutation

Medicine & Life Sciences

• Alternating hemiplegia of childhood 43%
• Anticonvulsants 23%
• Attention Deficit Disorder with Hyperactivity 25%
• Behavioral Symptoms 30%
• coenzyme Q10 32%
• Dextromethorphan 35%
• Efficiency 54%
• Epilepsy 20%
• Familial type 2 Hemiplegic migraine 48%
• Genes 40%
• Hemiplegia 30%
• Intellectual Disability 23%
• Learning 18%
• Maternal Inheritance 31%
• Memantine 33%
• Missense Mutation 25%
• Mutation 55%
• N-Methyl-D-Aspartate Receptors 100%
• Neurobehavioral Manifestations 30%
• Paresis 26%
• Partial Epilepsy 29%
• Seizures 38%
• Valproic Acid 27%
• Whole Exome Sequencing 29%